Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Qiagen ( (QGEN) ) is now available.
QIAGEN N.V. has reported a new total of 206,800,617 voting rights as of February 17, 2026, in line with disclosure requirements under Article 41 of the German Securities Trading Act. The update reflects an adjusted capital or related measure and confirms that there are no multiple voting rights outstanding, clarifying the current shareholder voting structure for investors.
By formally publishing the revised voting rights figure, QIAGEN provides greater transparency to capital markets across its European and U.S. listings. The announcement helps stakeholders assess ownership and influence within the company, supporting informed decisions by shareholders and analysts monitoring its corporate governance profile.
The most recent analyst rating on (QGEN) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. is a Netherlands-based life sciences company whose shares are listed on regulated markets in Frankfurt and several other German exchanges, as well as on the NYSE and Swiss venues. The company focuses on providing molecular diagnostics and sample preparation technologies used in research, clinical testing, and applied markets worldwide.
Average Trading Volume: 2,172,951
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.85B
Learn more about QGEN stock on TipRanks’ Stock Analysis page.